Aldeyra Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

Aldeyra's Q1 2026 filing reveals a company in a high-stakes transition from a high-burn clinical entity to a streamlined vehicle awaiting a binary regulatory outcome. The successful repayment of the Hercules loan and the aggressive reduction in operating expenses provide a temporary cushion, but the core value of the company remains tethered to the FDA's perception of reproxalap's efficacy. The shift to a lean model is a necessary survival tactic given the repeated regulatory setbacks. Ultimately, the investment thesis hinges on whether the current cash position is sufficient to fund the additional trials mandated by the FDA and whether AbbVie views the asset as viable. While the debt-free status is a positive milestone, the combination of a new class-action lawsuit and a third consecutive FDA rejection creates a risk profile that may outweigh the benefits of the reduced quarterly loss.